To the full analysis
Aurobindo Pharma stock: dividend
AUROPHARMA.NSWhat Aurobindo Pharma Limited pays out, how dependable that has been over the years, and whether free cash flow carries it. A dividend paid out of substance rather than out of the business is not a good dividend.
Daily figure as of 13 Nov 2026
Dividend yield over the last 12 months
0%
Dividend per share 2026
$0.04
paid in fiscal 2026
7%
no dividend in the last 12 months
$0.52
covers the dividend of $0.04
Aurobindo Pharma has paid no dividend in the last 12 months. The payout ratio and coverage therefore refer to the dividend paid in fiscal year 2026, not to a current payment.
The amounts for the last 12 months and paid in fiscal 2026 differ if the company has raised or cut its dividend since then.
Dividend dates and payments
Anyone holding the stock on the day before the ex-dividend date receives the dividend. Amounts are per share, before tax.
Last ex-dividend date
8 Aug 2025
$0.0425, paid 21 Aug 2025
Next ex-dividend date
not announced yet
Frequency
irregular
All 7 payments of the last five years
| Ex-dividend date | Payment date | Dividend per share |
|---|---|---|
| 8 Aug 2025 | 21 Aug 2025 | $0.0425 |
| 20 Feb 2024 | 4 Mar 2024 | $0.0159 |
| 20 Nov 2023 | 4 Dec 2023 | $0.0319 |
| 17 Feb 2023 | 3 Mar 2023 | $0.0319 |
| 6 Jun 2022 | 15 Jun 2022 | $0.0478 |
| 18 Feb 2022 | 4 Mar 2022 | $0.0159 |
| 17 Nov 2021 | 30 Nov 2021 | $0.0159 |
Dividend development
Dividend per share
Payout ratio
- of earnings
- of free cash flow
Figures as a table
| Year | Dividend per share | Earnings per share |
|---|---|---|
| 2007 | $0.00184 | $0.04 |
| 2008 | $0.00311 | $0.05 |
| 2009 | $0.00777 | $0.02 |
| 2010 | $0.00566 | $0.11 |
| 2011 | $0.00876 | $0.10 |
| 2012 | $0.00617 | −$0.02 |
| 2013 | $0.01230 | $0.05 |
| 2014 | $0.01084 | $0.29 |
| 2015 | $0.02780 | $0.29 |
| 2016 | $0.02441 | $0.37 |
| 2017 | $0.02070 | $0.42 |
| 2018 | $0.03980 | $0.44 |
| 2019 | $0.02649 | $0.43 |
| 2020 | $0.03186 | $0.52 |
| 2021 | $0.04250 | $0.97 |
| 2022 | $0.04783 | $0.48 |
| 2023 | $0.07973 | $0.35 |
| 2024 | $0.04782 | $0.58 |
| 2025 | $0.00019 | $0.64 |
| 2026 | $0.04253 | $0.64 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.